NMDA Modulation in Major Depressive Disorder

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. Therefore, this study will examine the efficacy and safety as well as cognitive function improvement of an NMDA enhancer (NMDAE) in the treatment of MDD in the adults.
Epistemonikos ID: 7010bbd4181789d52f24b54e954eba1d8bb60ebe
First added on: May 07, 2024